* AxoGen Inc AXGN.OQ AXGN.O is expected to show a rise
in
quarterly revenue when it reports results on March 14.
* The Alachua Florida-based company is expected to report
a
14.8% increase in revenue to $36.2 million from $31.54 million a
year ago, according to the mean estimate from 6 analysts, based
on Refinitiv data. The company's guidance on January 9 2023, for
the period ended December 31, was for revenue of $36.100
million.
* Refinitiv's mean analyst estimate for AxoGen Inc is for a
loss
of 11 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for AxoGen Inc
is
$16, above its last closing price of $7.88.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.13 -0.12 -0.01 Beat 91.8
Jun. 30 2022 -0.14 -0.14 -0.06 Beat 58.6
Mar. 31 2022 -0.16 -0.15 -0.20 Missed -30.4
Dec. 31 2021 -0.12 -0.13 -0.08 Beat 39.1
Sep. -0.14 -0.14 -0.09 Beat 34.4
30 2021
Jun. 30 2021 -0.13 -0.13 -0.09 Beat 29.9
Mar. 31 2021 -0.17 -0.16 -0.08 Beat 49.5
Dec. 31 2020 -0.11 -0.12 -0.08 Beat 35.6
This summary was machine generated March 10 at 13:43 GMT. All
figures in US dollars unless otherwise stated